Maxim Noeraparast (Amir Noeparast, Maxim Noeparast)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 4

Top Topics

Pluripotent Stem Cells

Top Venues

NPJ precision oncology

Cancer communications (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Oleg Timofeev, Philippe Giron, Steffen Lawo, Martin Pichler, Maxim Noeraparast
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework. NPJ precision oncology 8 (1) (2024)
Oleg Timofeev, Philippe Giron, Steffen Lawo, Martin Pichler, Maxim Noeraparast
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework. NPJ precision oncology 8 (1) (2024)
Maxim Noeraparast, Katarina Krajina, Renate Pichler, Dora Niedersüß-Beke, Shahrokh F Shariat, Viktor Grünwald, Sascha Ahyai, Martin Pichler
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies. Cancer communications (London, England) (2024)
Maxim Noeraparast, Philippe Giron, Alfiah Noor, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Carolien Eggermont, Hugo Vandenplas, Bram Boeckx, Diether Lambrechts, Jacques De Grève, Erik Teugels
CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition. Oncogene 38 (31) (2019)